BR112023007912A2 - Formas cristalinas de um composto inibidor de kras g12c - Google Patents

Formas cristalinas de um composto inibidor de kras g12c

Info

Publication number
BR112023007912A2
BR112023007912A2 BR112023007912A BR112023007912A BR112023007912A2 BR 112023007912 A2 BR112023007912 A2 BR 112023007912A2 BR 112023007912 A BR112023007912 A BR 112023007912A BR 112023007912 A BR112023007912 A BR 112023007912A BR 112023007912 A2 BR112023007912 A2 BR 112023007912A2
Authority
BR
Brazil
Prior art keywords
crystalline forms
kras
inhibitor compound
pharmaceutical composition
cancer
Prior art date
Application number
BR112023007912A
Other languages
English (en)
Inventor
Andrea Vaupel
Bo Liu
Catherine Leblanc
Christophe Mura
Liliane Jeanne Lorthiois Edwige
Heng Ge
Lijun Xue
Marc Gerspacher
Marie-Anne Lozac’H
Nadine Schneider
Nicolas Warin
Pascal Rigollier
Rainer Machauer
Rainer Wilcken
Robert Mah
Sinclair Strang Ross
Simona Cotesta
Stefan Stutz
Tanja Meister
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2020/125425 external-priority patent/WO2021120890A1/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112023007912A2 publication Critical patent/BR112023007912A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

formas cristalinas de um composto inibidor de kras g12c. trata-se de formas cristalinas de um composto inibidor de kras g12c e processos para sua preparação. ademais, é fornecida composição farmacêutica que compreende as ditas formas cristalinas e pelo menos um excipiente farmaceuticamente aceitável. a composição farmacêutica pode ser usada como um medicamento, em particular, para o tratamento de câncer e câncer de mutante kras g12c.
BR112023007912A 2020-10-30 2021-10-29 Formas cristalinas de um composto inibidor de kras g12c BR112023007912A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/CN2020/125425 WO2021120890A1 (en) 2019-12-20 2020-10-30 Pyrazolyl derivatives useful as anti-cancer agents
PCT/IB2020/062144 WO2021124222A1 (en) 2019-12-20 2020-12-17 Pyrazolyl derivatives useful as anti-cancer agents
CN2021101813 2021-06-23
PCT/CN2021/127601 WO2022089604A1 (en) 2020-10-30 2021-10-29 New crystalline forms of a kras g12c inhibitor compound

Publications (1)

Publication Number Publication Date
BR112023007912A2 true BR112023007912A2 (pt) 2024-01-02

Family

ID=81383573

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023007912A BR112023007912A2 (pt) 2020-10-30 2021-10-29 Formas cristalinas de um composto inibidor de kras g12c

Country Status (12)

Country Link
US (1) US20240116900A1 (pt)
EP (1) EP4237412A4 (pt)
JP (1) JP2023547194A (pt)
KR (1) KR20230098252A (pt)
CN (1) CN116472039A (pt)
AU (1) AU2021372796A1 (pt)
BR (1) BR112023007912A2 (pt)
CA (1) CA3199295A1 (pt)
IL (1) IL302359A (pt)
MX (1) MX2023005078A (pt)
TW (1) TW202233607A (pt)
WO (1) WO2022089604A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230107642A1 (en) 2020-12-18 2023-04-06 Erasca, Inc. Tricyclic pyridones and pyrimidones

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200639163A (en) * 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
JP2009530261A (ja) * 2006-03-16 2009-08-27 ファイザー・プロダクツ・インク ピラゾール化合物
EA201000113A1 (ru) * 2007-08-01 2010-08-30 Пфайзер Инк. Пиразольные соединения
CA2731146C (en) * 2008-07-24 2016-05-03 Nerviano Medical Sciences S.R.L. 3,4-diarylpyrazoles as protein kinase inhibitors
US9114137B2 (en) * 2010-08-03 2015-08-25 Nerviano Medical Sciences S.R.L. Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents
WO2015054572A1 (en) * 2013-10-10 2015-04-16 Araxes Pharma Llc Inhibitors of kras g12c
CN108069955B (zh) * 2016-11-14 2021-04-06 江苏恒瑞医药股份有限公司 3-吡啶基-4-苯并噻唑基吡唑类衍生物、其制备方法及其在医药上的应用
KR20190077048A (ko) * 2016-11-14 2019-07-02 지앙수 헨그루이 메디슨 컴퍼니 리미티드 3,4-비피리딜 피라졸 유도체, 그의 제조 방법 및 그의 의학적 적용
HUE061599T2 (hu) * 2017-11-15 2023-07-28 Mirati Therapeutics Inc KRas G12C inhibotorok
WO2019213516A1 (en) * 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
CA3099045A1 (en) * 2018-05-10 2019-11-14 Amgen Inc. Kras g12c inhibitors for the treatment of cancer
US11096939B2 (en) * 2018-06-01 2021-08-24 Amgen Inc. KRAS G12C inhibitors and methods of using the same
WO2021120890A1 (en) * 2019-12-20 2021-06-24 Novartis Ag Pyrazolyl derivatives useful as anti-cancer agents

Also Published As

Publication number Publication date
EP4237412A4 (en) 2024-04-10
EP4237412A1 (en) 2023-09-06
MX2023005078A (es) 2023-05-16
US20240116900A1 (en) 2024-04-11
CN116472039A (zh) 2023-07-21
AU2021372796A1 (en) 2023-06-01
CA3199295A1 (en) 2022-05-05
JP2023547194A (ja) 2023-11-09
TW202233607A (zh) 2022-09-01
KR20230098252A (ko) 2023-07-03
WO2022089604A1 (en) 2022-05-05
IL302359A (en) 2023-06-01

Similar Documents

Publication Publication Date Title
BR112020015688A8 (pt) Formulações tópicas que compreendem tofacitinibe
CL2018001371A1 (es) Uso de un inhibidor de b-raf y de un inhibidor de mek 1/2 para el tratamiento de un paciente que padece melanoma (divisional solicitud 201502807)
MX2020007625A (es) Inhibidor mtor, composicion farmaceutica y su uso.
BR112016001678A2 (pt) Composição, método de fabricação de um comprimido, comprimido, forma de dosagem unitária, artigo de fabricação, e, uso de uma composição, de um comprimido ou de uma forma de dosagem unitária
ECSP056194A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa
CL2021002963A1 (es) Nuevas formas cristalinas de n- (3- (2- (2-hidroxietoxia) -6-morfolinopiridin-4-yl) -4-methvlfenil) -2 (trifluorometil) isonicotinamida como inhibidores de la raf para el tratamiento del cáncer
AR057099A1 (es) Una forma cristalina, un proceso de preparacion y composicion farmaceutica
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
AR119158A1 (es) Tratamientos de angioedema hereditario
BR112022026186A2 (pt) Combinação de um inibidor de bromodomínio cbp/p300 e um inibidor de kras
CO2023013050A2 (es) Composiciones de psilocibina, métodos para prepararlas y métodos de uso de estas
AR115913A1 (es) Formas de dosificación oral biodisponibles, uso, métodos
PH12021550218A1 (en) Use of riluzole oral disintigrating tablets for treating diseases
CO2023008949A2 (es) Forma cristalina de tolebrutinib, método de preparación y uso de la misma
MX2020012377A (es) Uso de tabletas de desintegracion orales de riluzol para el tratamiento de enfermedades.
BR112023007912A2 (pt) Formas cristalinas de um composto inibidor de kras g12c
HUP0300709A2 (hu) Pemetrexedet monotioglikollal, L-ciszteinnel vagy tioglikolsavval együtt tartalmazó gyógyászati készítmény
CL2021003034A1 (es) Métodos de tratamiento del síndrome de sjögren utilizando un inhibidor de la tirosina quinasa de bruton
BR112023025738A2 (pt) Combinação de um inibidor de braf e um antagonista de ligação ao eixo pd-1, uso de uma combinação de um inibidor de braf e um antagonista de ligação ao eixo pd-1, método para o tratamento ou profilaxia de câncer, composição farmacêutica e invenção
BR112022000155A2 (pt) Composição inibidora da micromolécula pi4kiiia, seu método de preparação, e uso da mesma
AR123861A1 (es) Politerapia de antagonistas de unión al eje pd-1 e inhibidores de lrrk2
BR112022024937A2 (pt) Composto de alquenilpirimidina, método de preparação do mesmo, e aplicação do mesmo
BR112018068784A2 (pt) método para o tratamento de leucemia
PL425832A1 (pl) Genisteina oraz jej kompozycja do zastosowania w leczeniu choroby Alzheimera
CO2021000026A2 (es) Composición farmacéutica sinérgica de aceclofenaco y betametasona para el tratamiento del dolor en las formas localizadas de afecciones reumáticas